You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Characterization and quantification of tumor infiltrating lymphocytes in breast cancer
  1. Shahinaz Bedri1,
  2. Mahmoud Mohamed2,
  3. Hina Sarwath1 and
  4. Konduru Sastry1
  1. Aff1 grid.416973.e0000000405824340Department of ResearchWeill Cornell Medical College in Qatar Doha Qatar
  2. Aff2 grid.413548.f000000040571546XPharmacyHamad Medical Corporation Doha Qatar

https://doi.org/10.1186/2051-1426-2-S1-P9

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Tumor infiltrating lymphocytes (TILs) are a significant component of the tumor microenvironment [1]. In breast cancer the prognostic and predictive value of TIL is under active investigation [2]. The goal of our study was to define specific TIL subtypes and regional quantification in breast cancer of patients from the MENA region.

    Methodology

    47 FFPE samples with known clinic-pathological data were selected and studied using immunohistochemistry technique. TIL immune markers studied were CD3, CD8, CD45RO and FOXP3 and quantified by modified H-score system. Results were analyzed via SPSS.

    Results

    A positive correlation between CD3 and CD8 expression (rs=0.614, n=24, P 0.001) and CD3 and CD45RO expression (rs=0.621, n=24, P 0.001) were noted in the center of the tumor (CT).CD3 median percentage in CT was higher in grade 2 and grade 3 breast carcinoma compared to grade 1 (P 0.023). CD3 in the center of the tumor and CD8 in the invasive margins (IM) were significantly higher in ER/PR negative Her2/neu positive tumors compared to triple negative breast cancers. Lower CD3, CD8 and FOXP3 percentages were noticed in TNBC tumors. CD45RO median percentage was shown to be higher in the IM region.

    Conclusion

    TIL were affected by the patient clinic-pathological characteristics.

    References

    1. 1.↵
      1. Hanahan D,
      2. Weinberg RA
      . Hallmarks of cancer: the next generation. Cell. 2011;144:5646–74. doi:10.1016/j.cell.2011.02.013
      OpenUrlCrossRefPubMedWeb of Science
    2. 2.↵
      1. Mahmoud SM,
      2. Paish EC,
      3. Powe DG,
      4. Macmillan RD,
      5. Grainge MJ,
      6. Lee AH,
      7. Ellis IO,
      8. Green AR
      . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:151949–55. doi:10.1200/JCO.2010.30.5037
      OpenUrlAbstract/FREE Full Text